Kristin Lake, MD
Rheumatology · North Platte, NENPI 1548209174
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.4% of the total across 375 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 31 manufacturers reported payments, led by Amgen at 25.8% of the total.
Across 375 payments — averaging $18.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$2K
- AbbVie$926
- Lilly USA, LLC$612
- AstraZeneca$517
- Johnson & Johnson$443
- UCB, Inc.$436
- plus $2K from 25 others
What the payments were for
- Food & beverage$6,58897%
- Education$1743%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 94 | $1,742 |
| AbbVie | 47 | $926 |
| Lilly USA, LLC | 40 | $612 |
| AstraZeneca(2 entities) | 23 | $517 |
| Johnson & Johnson | 26 | $443 |
| UCB, Inc. | 28 | $436 |
| Mallinckrodt Hospital Products Inc. | 12 | $384 |
| Aurinia Pharma U.S., Inc. | 24 | $375 |
| Novartis | 15 | $250 |
| Bristol Myers Squibb | 14 | $176 |
| Sandoz | 7 | $156 |
| GSK | 10 | $149 |
| Novo Nordisk | 8 | $122 |
| Pfizer | 3 | $60 |
| Sanofi | 3 | $51 |
| ANI Pharmaceuticals, Inc. | 2 | $50 |
| Philips North America LLC | 3 | $46 |
| Boehringer Ingelheim | 2 | $38 |
| Fresenius Kabi USA, LLC | 2 | $36 |
| Ultragenyx Pharmaceutical Inc. | 1 | $20 |
| Boston Scientific | 1 | $19 |
| Mallinckrodt Enterprises LLC | 1 | $19 |
| Acadia Pharmaceuticals Inc | 1 | $17 |
| Otsuka America Pharmaceutical, Inc. | 1 | $17 |
| Octapharma USA, Inc. | 1 | $17 |
| Regeneron Healthcare Solutions, Inc. | 1 | $15 |
| Genentech, Inc. | 1 | $15 |
| Genentech USA, Inc. | 1 | $15 |
| Electromed, Inc. | 1 | $14 |
| Kowa Pharmaceuticals America, Inc. | 1 | $12 |
| Merck | 1 | $12 |
How this compares
$6,762 in reported general payments places this provider in the 75th percentile of 39 rheumatology providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Enbrel MiniEtanercept | 20 | $146,973 |
| RinvoqUpadacitinib | 16 | $104,946 |
| Humira PenAdalimumab | 12 | $96,389 |
| Taltz AutoinjectorIxekizumab | 11 | $71,424 |
| Hydroxychloroquine Sulfate | 261 | $14,193 |
| MethotrexateMethotrexate Sodium | 315 | $13,831 |
| Leflunomide | 41 | $2,924 |
| Pregabalin | 28 | $2,280 |
| Azathioprine | 23 | $1,608 |
| Celecoxib | 57 | $1,599 |
| Fentanyl | 12 | $1,318 |
| Mycophenolate Mofetil | 25 | $1,245 |
| Sulfasalazine DrSulfasalazine | 42 | $1,173 |
| Gabapentin | 41 | $1,097 |
| Prednisone | 120 | $935 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRinvoq | $926 | $104,94616 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 39 rheumatology providers in Nebraska.
Other rheumatology in North Platte
- Nadia EliasNorth Platte$2K
- Loretta BacaNorth Platte$158
- Abhijeet DanveOmaha$118K
- Jay KenikOmaha$69K
- Lynell KlassenOmaha$68K
- William PalmerOmaha$24K
- Ted MikulsOmaha$23K
- Melvin ChurchillLincoln$14K
- Amandeep RakhraOmaha$12K
- Diana MeylerLincoln$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.